公开(公告)号：US20240132964A1

公开(公告)日：2024-04-25

申请号：US18546611

申请日：2022-02-16

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  UNIVERSITÉ PARIS CITÉ ,  FONDATION IMAGINE ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)

发明人： Mickaël MENAGER ,  Julie TOUBIANA ,  Darragh DUFFY ,  Frédéric LAUCAT

IPC分类号： C12Q1/6883

CPC分类号： C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/158

摘要： SARS-CoV-2 infection in children is generally milder than in adults, yet a proportion of cases result in hyperinflammatory conditions often including myocarditis. To better understand these cases, the inventors applied a multi-parametric approach to the study of blood cells of 56 children hospitalized with suspicion of SARS-CoV-2 infection. The most severe forms of MIS-C (multisystem inflammatory syndrome in children related to SARS-CoV-2), that resulted in myocarditis, were characterized by elevated levels of pro-angiogenesis cytokines and several chemokines. This phenotype was associated with TNF-α signaling, sustained NF-κB signaling in monocytic/dendritic cells, alongside increased HIF-1α and VEGF signaling. Single-cell transcriptomic analyses identified

公开(公告)号：US20240075063A1

公开(公告)日：2024-03-07

申请号：US18256788

申请日：2021-12-09

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE DE PARIS ,  ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS

发明人： Sophie CAILLAT-ZUCMAN ,  Nana TALVARD-BALLAND

IPC分类号： A61K35/17 ,  A61P35/02

CPC分类号： A61K35/17 ,  A61P35/02 ,  A61K2035/124

摘要： The inventors explored in an allogeneic situation the regulatory potential of Mucosal-Associated Invariant T cells (MAIT cells), a population of unconventional T cells that exhibit potent antibacterial activity, expressing a semi-invariant TCR which recognizes vitamin B2 derivatives of microbial origin presented by the MR1 molecule. In particular, the inventors used i) an allogenic reaction model in vitro (mixed lymphocyte reaction, MLR) and ii) murine model of xenogeneic aGvHD They first verified that human MAIT cells do not proliferate in response to allogeneic stimulation in vitro (MLR) or in vivo (immunodeficient mice) alone but require for their expansion both an inflammatory environment and TCR ligation by its ligand. In contrast, MAIT cells are able to inhibit the proliferation of allospecific LT in vitro in a dose-dependent manner. Furthermore, the adoptive transfer of MAIT cells in a mouse model of xeno-GVHD resulted in a delay in early or late GvHD development. Altogether, these data describe a new regulatory function of MAIT cells in an allogeneic context, allowing us to consider their use in cell therapy to limit GvHD.

公开(公告)号：US20230390309A1

公开(公告)日：2023-12-07

申请号：US18031632

申请日：2021-10-14

申请人： INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE ,  INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  SORBONNE UNIVERSITE ,  UNIVERSITE PARIS-SACLAY

发明人： BRUNO FIGADERE ,  RITA RAISMAN-VOZARI ,  PATRICK PIERRE MICHEL ,  LAURENT FERRIE ,  CLÉMENCE ROSE

IPC分类号： A61K31/65 ,  C07C231/12 ,  C07C235/84 ,  A61P25/28

CPC分类号： A61K31/65 ,  C07C231/12 ,  C07C235/84 ,  A61P25/28 ,  C07C2603/46

摘要： The present invention relates to the field of medicine. In particular, it relates to the use of tetracycline derivatives in the treatment or prevention of a neurodegenerative or neuroinflammatory disease, such as Parkinson's disease.

公开(公告)号：US20230365936A1

公开(公告)日：2023-11-16

申请号：US18319224

申请日：2023-05-17

申请人： FUJIFILM Corporation ,  Assistance Publique - Hôpitaux de Paris

发明人： Nisa K. E. RENAULT ,  Michele L. Hamrick ,  Chad H. Koonce ,  Philippe Menasche ,  Valerie Bellamy ,  Camille Humbert ,  Guillaume Churlaud ,  Jerome Larghero

IPC分类号： C12N5/0775 ,  C12N5/00 ,  A61P9/10

CPC分类号： C12N5/0662 ,  C12N5/0031 ,  A61P9/10 ,  C12N2501/998 ,  C12N2501/115

摘要： The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesicles, and fractions thereof. The present disclosure further provides methods for analyzing activities, and the functionality and potency, of such secretomes, extracellular vesicles, and fractions thereof. The present disclosure also relates to the therapeutic use of secretomes, extracellular vesicles, and fractions thereof. The present disclosure further relates to a good manufacturing practices (GMP)-ready, scalable, culture protocol for the release of clinic-ready secretomes.

公开(公告)号：US20230293577A1

公开(公告)日：2023-09-21

申请号：US18042187

申请日：2021-08-19

申请人： ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  UNIVERSITÉ PARIS CITÉ

发明人： Hang Korng EA ,  Vincent BOUDY ,  Amélie WOJCICKI ,  Sophie DUFAY

IPC分类号： A61K33/04 ,  A61K9/06 ,  A61K47/36 ,  A61K31/198 ,  A61K31/19 ,  A61K31/194 ,  A61K33/42 ,  A61K33/06 ,  A61K38/17 ,  A61K38/46 ,  A61K38/19 ,  A61P3/14

CPC分类号： A61K33/04 ,  A61K9/06 ,  A61K31/19 ,  A61K31/194 ,  A61K31/198 ,  A61K33/06 ,  A61K33/42 ,  A61K38/1709 ,  A61K38/19 ,  A61K38/465 ,  A61K47/36 ,  A61P3/14

摘要： The invention concerns an alginate hydrogel or a new composition derived therefrom further comprising another calcium chelator such as sodium thiosulfate and/or calcium crystal solubilizer or inhibitor, and their use in the treatment of ectopic calcifications or disorders comprising ectopic calcifications.

公开(公告)号：US20230279438A1

公开(公告)日：2023-09-07

申请号：US17998603

申请日：2021-05-12

申请人： INSERM (Institut National de la Santé et la Recherche Médicale) ,  Université Paris Cité ,  Assistance Publique-Hôpitaux de Paris ,  Fondation Imagine

发明人： Annarita MICCIO ,  Panagiotis ANTONIOU ,  Marina CAVAZZANA

IPC分类号： C12N15/90 ,  C12N9/78 ,  C12N9/22 ,  C12N15/11

CPC分类号： C12N15/90 ,  C12N9/22 ,  C12N9/78 ,  C12N15/11 ,  C12Y305/04005 ,  C12N2310/20 ,  C12N2320/34

摘要： The clinical history of β-hemoglobinopathies shows that the severity is mitigated by the synthesis of the fetal γ-globin in adulthood, typically associated with genetic variants the HBB cluster known as hereditary persistence of fetal hemoglobin (HPFH) mutations. The inventors identified that most of the known HPFH mutations in the γ-globin promoters (C>T, G>A, T>C or A>G) can be recapitulated using CBE- and ABE-mediatedbase-editing approaches. In particular, the inventors designed gRNAs that, when combined with CBEs or ABEs, generate HPFH mutations, and either disrupt binding sites for transcriptional repressors (-200 and -115 sites) or generate de novo DNA motifs recognized by transcriptional activators (e.g., -198 T>C, the -175 T>C and -113 A>G). It is noteworthy that a subset of the gRNAs targeting the -200 and the 115 regions are predicted to generate simultaneously HPFH mutations and also to make base changes other than HPFH mutations in or around the LRF and BCL11A binding sites, which might further reduce LRF and BCL11A occupancy. Accordingly, the present invention relates to base editing approaches for the treatment of β-hemoglobinopathies.

公开(公告)号：US20230266322A1

公开(公告)日：2023-08-24

申请号：US18003999

申请日：2021-06-28

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  SORBONNE UNIVERSITÉ ,  Université Paris Cité

发明人： Franck PAGES ,  Jérôme GALON ,  Guy ZEITOUN ,  Amos KIRILOVSKY

IPC分类号： G01N33/574

CPC分类号： G01N33/574 ,  G01N2800/54

摘要： The inventors assessed in locally advanced rectal cancer whether a diagnostic biopsy-adapted Immunoscore (ISB) could predict response to neoadjuvant treatment (nT) and better define patients eligible to a postoperative adjuvant therapy. The inventors showed that ISB was an independent parameter, more informative than pre- (P

公开(公告)号：US11718661B2

公开(公告)日：2023-08-08

申请号：US17288013

申请日：2019-10-29

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Sorbonne Université ,  Assistance Publique-Hôpitaux de Paris (APHP)

发明人： Guy Gorochov ,  Martin Larsen ,  Delphine Sterlin ,  Jehane Fadlallah

IPC分类号： C07K16/12 ,  A61P37/04 ,  A61P1/00 ,  A61K9/00 ,  A61K39/00

CPC分类号： C07K16/1271 ,  A61K9/0053 ,  A61P1/00 ,  A61P37/04 ,  A61K2039/505 ,  A61K2039/542 ,  C07K2317/33

摘要： The invention is in the field of therapy of antibody deficiencies. Inventors demonstrate for the first time in both controls and IgA-deficient patients, systemic anti-microbiota IgG responses correlate with reduced inflammation suggesting that systemic IgG responses contribute to the gut microbiota confinement. Furthermore, SIgAd-associated inflammation is inversely correlated with systemic anti-commensal IgG responses, which may thus serve as a second line of defense. Altogether, these data suggest that systemic IgG and intestinal IgA cooperate in different body compartments to limit systemic pro-inflammatory pathways. As selective IgA deficient patients harbour elevated seric anti-commensal IgG levels, these findings suggest that in selective IgA deficiency, microbiota confinement is obtained at the price of a strong inflammatory response. Accordingly, the invention relates to a composition containing immunoglobulins A (IgA), more particularly secretory IgA, for use by oral administration in the prevention or treatment of antibody deficiencies such as SIgAd (Selective IgA deficiency) or common variable immunodeficiency (CVID) and associated inflammatory diseases.

公开(公告)号：US20230235408A1

公开(公告)日：2023-07-27

申请号：US18003535

申请日：2021-06-28

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  SORBONNE UNIVERSITÉ ,  UNIVERSITÉ DE PARIS

发明人： Franck PAGES ,  Jérôme GALON ,  Guy ZEITOUN ,  Amos KIRILOVSKY

IPC分类号： C12Q1/6886 ,  G01N33/574 ,  G01N33/569

CPC分类号： C12Q1/6886 ,  G01N33/57419 ,  G01N33/56972 ,  G01N2800/52 ,  C12Q1/6869

摘要： The inventors assessed in locally advanced rectal cancer whether a diagnostic biopsy-adapted Immunoscore (ISg) could predict response to neoadjuvant treatment (nT) and better define patients eligible to an organ preservation strategy (“Watch-and-Wait”). The inventors showed that ISB was an independent parameter, more informative than pre- (P

公开(公告)号：US20230151425A1

公开(公告)日：2023-05-18

申请号：US17905899

申请日：2021-03-10

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Sorbonne Université ,  Université Paris Cité ,  Assistance Publique-Hôpitaux de Paris ,  Fondation Asile des Aveugles

发明人： Francine BEHAR-COHEN ,  Min ZHAO

IPC分类号： C12Q1/6883 ,  A61K31/585

CPC分类号： C12Q1/6883 ,  A61K31/585 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： Central Serous chorioretinopathy (CSCR) is primarily an ocular disease, affecting the choroid and the retinal pigment epithelium. To date, no systemic biomarker of CSCR have been discovered that could link both forms and help the diagnosis in challenging cases. In the present invention, the inventors measure in European cohorts of CSCR patients (n=168) with (n=90) or without epitheliopathy (n=78) and a cohort of 153 control subjects without any ocular disease history, the serum levels of NGAL and the NGAL/MMP9 complex. Serum NGAL (ng/ml) was significantly higher in the control group (108.8±46.8) than in the CSCR cohort (80.4±46.4, p